Basilea Announces Positive Results of Phase 3 ERADICATE Study with Ceftobiprole in Staphylococcus Aureus Bacteremia (SAB)
Ceftobiprole met primary and secondary efficacy endpoints
Basilea plans to submit a New Drug Application (NDA) in the U.S. around year end 2022
Basel, Switzerland, June 28, 2022 -- Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | New Drug Applications | Pharmaceuticals | Staphylococcus Aureus | Study | Switzerland Health